Press Releases March 31, 2026 07:00 AM

GlobalFoundries Announces Conference Call to Review First Quarter 2026 Financial Results

GlobalFoundries schedules Q1 2026 earnings call and Investor Day to discuss financial results and strategic outlook

By Priya Menon
Share
Twitter Reddit Facebook LinkedIn
GFS

GlobalFoundries announced a conference call for May 5, 2026, to review its first quarter 2026 financial results, followed by an Investor Day on May 7, 2026, where company leadership will discuss growth initiatives and the long-term outlook. The company is a key semiconductor manufacturer serving various high-growth markets globally.

GlobalFoundries Announces Conference Call to Review First Quarter 2026 Financial Results
GFS
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • GlobalFoundries will report Q1 2026 financial results on May 5, 2026.
  • Investor Day on May 7, 2026, will highlight company strategy and growth initiatives.
  • GlobalFoundries serves critical sectors including automotive, smart mobile devices, IoT, and communications infrastructure.

MALTA, N.Y., March 31, 2026 (GLOBE NEWSWIRE) -- GlobalFoundries (NASDAQ: GFS) today announced that it will host a conference call on Tuesday, May 5, 2026, at 8:30 a.m. ET following the release of the company’s first quarter 2026 financial results.

Conference Call and Webcast Information

The company will host a conference call with the financial community on Tuesday, May 5, 2026, at 8:30 a.m. ET. Interested parties may join the scheduled conference call by registering here.

The company’s financial results and a webcast of the conference call will be available on GlobalFoundries’ Investor Relations website at https://investors.gf.com.

2026 Investor Day

Following the first quarter financial results on May 5, GlobalFoundries will host its Investor Day on Thursday, May 7, 2026, beginning at 9:00 a.m. ET in New York City. The event will feature presentations from GlobalFoundries’ leadership team on the company’s strategy, growth initiatives, and long-term outlook, followed by a Q&A session. Further details and webcast registration is available here.

About GF

GlobalFoundries (GF) is a leading manufacturer of essential semiconductors the world relies on to live, work and connect. We innovate and partner with customers to deliver more power-efficient, high-performance products for the automotive, smart mobile devices, internet of things, communications infrastructure and other high-growth markets. With our global manufacturing footprint spanning the U.S., Europe, and Asia, GF is a trusted and reliable source for customers around the world. Every day, our talented, global team delivers results with an unwavering focus on security, longevity, and sustainability. For more information, visit www.gf.com.

© 2026 GlobalFoundries Inc. GF®, GlobalFoundries®, the GF logos and other GF marks are trademarks of GlobalFoundries Inc. or its subsidiaries. All other trademarks are the property of their respective owners. 

For further information, please contact:
                 
[email protected]


Risks

  • Financial results may not meet market expectations affecting investor sentiment.
  • Growth initiatives could face execution challenges impacting future performance.
  • Global semiconductor market volatility and supply chain disruptions may affect business outcomes.

More from Press Releases

Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease Jun 13, 2026 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026 Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema Jun 13, 2026 Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules Jun 12, 2026 Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1 Jun 12, 2026